Euclidean Capital LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001825034

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocused how tags are computed

Q2 2026 · 11 positions · Total reported value $439.84M · Top-10 concentration 100.0% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 9.1% · 1 new · 0 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +9.8% · vs SPY -5.0% · Prev Value $392.31M — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, Euclidean Capital LLC disclosed 11 equity positions with a combined reported value of $439.84M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused.

The largest disclosed positions as of Q2 2026 were VEU ($271.64M), VTV ($113.32M), INDA ($18.25M). By sector, the heaviest allocations are Health Care 6.3%, Other 93.7%. Versus the prior quarter, allocation shifted toward Other (+1.2pp) and away from Health Care (-1.2pp).

Versus the prior quarter, Euclidean Capital LLC opened 1 new positions, trimmed 0 and fully exited 0, a turnover rate of 9.1% of positions. The portfolio's overlap with the prior quarter was 91% of names.

The largest new positions opened in Q2 2026 were TMS ($9.04M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • TMS TEAMSHARES INC · $9.04M

Fully Exited (vs previous quarter)

No tracked position was fully exited this quarter.

Insider Transactions (Form 4)

Latest Euclidean Capital LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Euclidean Capital LLC is an SEC-registered 13F filer. As of Q2 2026 it reported 11 US equity positions with a combined value of $439.84M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 11 positions · $439.84M reported value (Q2 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: VEU (VANGUARD INTL EQUITY INDEX F) at 61.8%
  • Average position size: $39.99M

Sector Tilt

  • Health Care 6.3%
  • (classified holdings cover 6% of value)

Quarterly Activity

  • Q2 2026: 1 new
  • 10 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: Euclidean Capital LLC appears to maintain a conservative stance, with a preference for holding positions steady, indicated by a lack of significant changes in shareholdings. The portfolio is well-diversified across sectors, with a focus on holding rather than active trading. 2. Key Moves: - Addition: A new position was established in TEAMSHARES INC (TMS), which is a healthcare company. - No Reductions: No holdings were sold, suggesting a holding pattern with existing investments. - No Increase or Decrease: Share counts in the top-10 holdings remained the same quarter-over-quarter. 3. Portfolio Structure: - Passive/Active: The fund appears to have a passive structure, with a significant allocation to Vanguard ETFs, which are known for their index-fund approach. - Sector Bias: The portfolio is tilted towards healthcare with three companies and four ETFs in the healthcare sector, reflecting a sector bias. - Risk Appetite: The portfolio has a moderate risk appetite, given the conservative approach and the presence of established and diversified ETFs. 4. Per-Holding One-Liner: - VEU: Vanguard's international equity index fund, tracking a broad international market index. - VTV: Vanguard's total stock market ETF, tracking the performance of the U.S. stock market. - INDA: iShares Trust's Total Return Bond ETF, a broad-based fixed income ETF. - ORIC: ORIC Pharmaceuticals Inc., a biopharmaceutical company focused on the development of cancer therapies. - TMS: TeamShares Inc., a healthcare company involved in biotechnology. - FHTX: Foghorn Therapeutics Inc., a biopharmaceutical company specializing in neurodegenerative diseases. - PMVP: PMV Pharmaceuticals, a biotechnology company focusing on oncology. - ALEC: Alector Inc., a biopharmaceutical company developing treatments for Alzheimer's disease and related neurodegenerative conditions. - SRZN: SurroZene Inc., a biotechnology company. - TNYA: Tenaya Therapeutics Inc., a biotechnology company. 5. One-Sentence Style Summary: Euclidean Capital LLC maintained a steady and diversified portfolio in Q2 2026, with a conservative approach favoring Vanguard ETFs and healthcare sector exposure.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Other 93.7%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 3.24M $271.64M 61.76%
61.76%
Hold
2 520.00K $113.32M 25.77%
25.77%
Hold
3 369.60K $18.25M 4.15%
4.15%
Hold
4 989.41K $10.72M 2.44%
2.44%
Hold
5 1.10M $9.04M 2.06%
2.06%
New
6 1.57M $7.68M 1.75%
1.75%
Hold
7 2.63M $3.52M 0.80%
0.80%
Hold
8 1.31M $2.63M 0.60%
0.60%
Hold
9 87.70K $2.28M 0.52%
0.52%
Hold
10 1.02M $750.71K 0.17%
0.17%
Hold
11 170.83K $2.82K 0.00%
0.00%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 90% R 90% F1 90% (modelled on 2026-Q1; 9/10 hit)

Historical Backtest (10 quarters)

Avg precision 93% · recall 93% · F1 93% · avg rank error 1.2 · Top-10 turnover 6%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 100% 100% 100% SPY · GLD · INDA · RAPT · ALEC · FHTX · ME · ORIC · PMVP · TNYA SPY · INDA · GLD · ORIC · FHTX · ALEC · RAPT · ME · TNYA · PMVP
2024-Q2 90% 90% 90% SPY · INDA · GLD · ORIC · FHTX · ALEC · RAPT · ME · TNYA · PMVP SPY · INDA · FHTX · ORIC · ALEC · PMVP · ME · TNYA · RAPT · SRZN
2024-Q3 90% 90% 90% SPY · INDA · FHTX · ORIC · ALEC · PMVP · ME · TNYA · RAPT · SRZN SPY · INDA · VEU · FHTX · ORIC · ALEC · PMVP · ME · TNYA · RAPT
2024-Q4 90% 90% 90% SPY · INDA · VEU · FHTX · ORIC · ALEC · PMVP · ME · TNYA · RAPT SPY · INDA · VEU · ORIC · FHTX · PMVP · ALEC · TNYA · SRZN · RAPT
2025-Q1 100% 100% 100% SPY · INDA · VEU · ORIC · FHTX · PMVP · ALEC · TNYA · SRZN · RAPT INDA · VEU · FHTX · ORIC · PMVP · SPY · ALEC · SRZN · RAPT · TNYA
2025-Q2 100% 100% 100% VEU · INDA · FHTX · ORIC · PMVP · SPY · ALEC · SRZN · RAPT · TNYA VEU · INDA · ORIC · FHTX · PMVP · SPY · ALEC · SRZN · RAPT · TNYA
2025-Q3 100% 100% 100% VEU · INDA · ORIC · FHTX · PMVP · SPY · ALEC · SRZN · TNYA · RAPT VEU · INDA · ORIC · FHTX · ALEC · PMVP · SPY · RAPT · TNYA · SRZN
2025-Q4 90% 90% 90% VEU · INDA · ORIC · FHTX · ALEC · PMVP · SPY · RAPT · TNYA · SRZN VEU · VTV · INDA · FHTX · ORIC · PMVP · SPY · RAPT · ALEC · SRZN
2026-Q1 80% 80% 80% VEU · VTV · INDA · FHTX · ORIC · PMVP · SPY · RAPT · ALEC · SRZN VEU · VTV · INDA · ORIC · FHTX · PMVP · ALEC · SRZN · TNYA · SRZNW
2026-Q2 ★ 90% 90% 90% VEU · VTV · INDA · ORIC · FHTX · PMVP · ALEC · SRZN · TNYA · SRZNW VEU · VTV · INDA · ORIC · TMS · FHTX · PMVP · ALEC · SRZN · TNYA

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Euclidean Capital LLC buy in 2026-Q2?

In its 2026-Q2 13F filing, Euclidean Capital LLC reported 11 equity positions worth $439.84M in aggregate; its largest disclosed positions were VEU ($271.64M), VTV ($113.32M), INDA ($18.25M).

How large is Euclidean Capital LLC's portfolio?

Euclidean Capital LLC reported $439.84M of long equity holdings across 11 positions as of 2026-Q2. Top-10 holdings account for 100.0% of reported value.

What is Euclidean Capital LLC's investment style?

HoldingsHub classifies the portfolio as Small / Focused, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/euclidean-capital/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →